National Research Corporation

NRC Healthcare Health Information Services

National Research Corporation’s revenue for fiscal 2025 (year ended December 2025) was $137.4 million, down 3.96% from fiscal 2024. In the quarter to June 2026, revenue grew 3.98%, EPS fell 3,091.5%, free cash flow grew 101.5% and total debt rose 11.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years; insiders bought in the last twelve months.

20.15 0.96 −4.55%
Market cap
$466.9M
P/E
80.6×
Fwd P/E
4.9×
Dividend yield
3.18%
F-score
6/9
Altman Z
3.33
Beneish M
−3.10
Dividend safety
45/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

66.87% 49.88% 40.43% 39.82%
Piotroski F-Score
6 6 5 5
ROA
12.23% 8.45% 6.47% 4.00%
ROIC
19.51% 16.64% 14.39% 10.32%
Return on Tangible Assets
70.38% 46.93% 40.00% 20.34%
Average Days of Receivables
33.45 30.91 29.79 35.59
Free Cash Flow per Share
0.53 0.70 0.80 0.98
Free Cash Flow
11.62 15.74 17.43 21.64
Capital Expenditures
(14.03) (10.71) (9.55) (7.87)
Other line items
Cash ROIC
12.56% 16.90% 19.35% 22.57%
Accounts Receivable Turnover
11.38 12.04 12.17 10.56
Accounts Payable Turnover
28.67 44.33 24.88 42.74
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
7.56 8.15 15.35 9.04
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Tax Rate
(0.30) (0.35) (0.38) (0.38)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
37.25% 39.89% 41.74% 45.06%
Share Based Compensation of Revenue
1.14% 2.41% 3.43% 8.44%
Interest Coverage
6.68 4.74 3.82 2.73
Operating CF/Net income
1.57 2.34 3.09 5.32
Depreciation/Fixed assets
0.17 0.19 0.21 0.22
Capex/Depreciation
(1.98) (1.39) (1.14) (0.90)
Revenue per Share
6.29 6.14 6.36 6.36
Operating CF per Share
1.16 1.18 1.24 1.34
Capex per Share
(0.63) (0.48) (0.44) (0.36)
Capex to Sales
0.10 0.08 0.07 0.06

Fold the line items

Columns are period end dates